Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide is selected from the group QPEGHHWETQQIPSLS (SEQ ID No. 103； p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98； p8461), TQQIPSLSPSQ (SEQ ID No. 99； p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100； p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101； p9269-Cl), and QPEGHHWETQQIPSLSP (SEQ ID No. 102； p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103； p8322) and wherein said IL-23 related disease is selected from the group psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies (ANCA-) associated vasculitides, neurodegenerative diseases, preferably M. Alzheimer or multiple sclerosis, atopic dermatitis, graft- versus-host disease, cancer, preferably Oesophagal carcinoma, colorectal carcinoma, lung adenocarcinoma, small cell carcinoma, and squamous cell carcinoma of the oral cavity, especially psoriasis, neurodegenerative diseases or IBD.L'invention concerne un vaccin utilisable de préférence pour la prévention ou le traitement d'une maladie liée à l'interleukine 23 (IL-23), qui comprend un peptide lié à un support pharmaceutiquement acceptable, ledit peptide étant choisi dans le groupe QPEGHHWETQQIPSLS (SEQ ID No 103； p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No 98； p8461), TQQIPSLSPSQ (SEQ ID No 99； p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No 100； p9269), QPEGHHWETQQIPSLSPS (SEQ ID No 101； p9269-Cl), et QPEGHHWETQQIPSLSP (SEQ ID No 102； p9269-C2), en particulier QPEGHHWETQQIPSLS (SEQ ID No 103； p8322). Cette maladie liée à IL-23 est choisie dans le groupe co
